

ACADIA PHARMACEUTICALS INC

Form 4

August 02, 2005

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box
 if no longer
 subject to
 Section 16.
 Form 4 or
 Form 5
 obligations
 may continue.
See Instruction
 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

OXFORD BIOSCIENCE
 PARTNERS IV LP

(Last) (First) (Middle)

222 BERKELEY ST.

(Street)

BOSTON, MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading

Symbol

ACADIA PHARMACEUTICALS
 INC [ACAD]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

____ Director ____X____ 10% Owner
 ____ Officer (give title below) ____ Other (specify below)

3. Date of Earliest Transaction
 (Month/Day/Year)

07/29/2005

4. If Amendment, Date Original
 Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

____ Form filed by One Reporting Person
 ____X____ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D)	Code V Amount (D) Price		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transaction Code	5. Number of Derivative Securities	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Year)	(Instr. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)							
			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Common Stock Warrant (right to buy)	\$ 8.148	07/29/2005	P		89,900		10/17/2005	04/19/2010	Common Stock	89,900	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
OXFORD BIOSCIENCE PARTNERS IV LP 222 BERKELEY ST. BOSTON, MA 02116		X		
MRNA FUND II LP 222 BERKELEY ST. BOSTON, MA 02116		X		
OBP MANAGEMENT IV LP 222 BERKELEY ST. BOSTON, MA 02116		X		
BARNES JEFFREY T 222 BERKELEY ST. BOSTON, MA 02116		X		
CARTHY MARK 222 BERKELEY ST. BOSTON, MA 02116		X		
FLEMING JONATHAN 222 BERKELEY ST. BOSTON, MA 02116		X		
LYTTON MICHAEL 222 BERKELEY ST. BOSTON, MA 02116		X		
WALTON ALAN G 222 BERKELEY ST. BOSTON, MA 02116	X	X		

Signatures

/s/ Raymond Charest, as attorney-in-fact for Jonathan J. Fleming, as general partner of the general partner of Oxford Bioscience Partners IV L.P. 08/02/2005

__Signature of Reporting Person Date

/s/ Alexia Pearsall, as attorney-in-fact for Jonathan J. Fleming, as general partner of the general partner of mRNA Fund II L.P. 08/02/2005

__Signature of Reporting Person Date

/s/ Raymond Charest, as attorney-in-fact for Jonathan J. Fleming, as general partner of OBP Management IV L.P. 08/02/2005

__Signature of Reporting Person Date

/s/ Raymond Charest, as attorney-in-fact for Jeffrey T. Barnes 08/02/2005

__Signature of Reporting Person Date

/s/ Raymond Charest, as attorney-in-fact for Mark P. Carthy 08/02/2005

__Signature of Reporting Person Date

/s/ Raymond Charest, as attorney-in-fact for Jonathan J. Fleming 08/02/2005

__Signature of Reporting Person Date

/s/ Michael E. Lytton 08/02/2005

__Signature of Reporting Person Date

/s/ Raymond Charest, as attorney-in-fact for Alan G. Walton 08/02/2005

__Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Securities held of record by Oxford Bioscience Partners IV L.P. ("Oxford IV"). By virtue of their relationship as affiliated limited partnerships, whose sole general partner shares individual general partners, Oxford IV and mRNA Fund II L.P. ("mRNA") may be deemed to share voting power and the power to direct the disposition of the shares which each partnership owns of record. OBP

- (1) Management IV L.P. ("OBP IV") (as the general partner of Oxford IV), may also be deemed to own beneficially the shares held of record by Oxford IV. Each of Messrs. Barnes, Carthy, Fleming, Lytton, and Walton (who is a Director of the Issuer), the individual general partners of OBP IV, may be deemed to own beneficially the shares held by Oxford IV. The reporting persons disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.